|
Accueil > Actualité
Bristol-Myers Squibb: receives EU approval for Sprycel
(CercleFinance.com) - US drugmaker Bristol-Myers Squibb said that the European Commission has approved its leukemia drug Sprycel for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
In a a Phase 2 trial, the combination of Sprycel and chemotherapy showed an overall survival rate of 91.5%, the company said. Sprycel is currently approved in over 60 countries for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Copyright (c) 2019 CercleFinance.com. All rights reserved. |
19/04/2024 16:35
TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables 19/04/2024 15:53 L'Oréalentouré après ses ventes trimestrielles 19/04/2024 15:45 Nissanrévision à la baisse des prévisions sur l'exercice Tous les articles sociétés |
